Physician profile
David L Cunningham
NPI 1891891594
$16,743.77
in general payments reported to CMS, 2019-2025
46 companies · $13.73 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,250 · 2020: $4,839 · 2021: $4,383 · 2022: $1,403 · 2023: $1,642 · 2024: $213 · 2025: $13.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.57 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laser Specialty Medical, LLC | $9,500.00 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $923.84 | 2021-2023 | Prolaris |
| Astellas Pharma US INC | $908.61 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $898.27 | 2019-2024 | |
| Janssen Biotech, INC. | $685.84 | 2019-2024 | Erleada |
| Coloplast Corp | $557.58 | 2019-2022 | |
| Myovant Sciences INC. | $371.70 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $274.30 | 2023-2024 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals LP | $224.19 | 2020-2022 | |
| Medtronic USA, INC. | $172.26 | 2020 | |
| Urovant Sciences INC | $154.89 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $151.50 | 2019-2022 | |
| Axonics, INC. | $148.19 | 2020-2024 | Axonics |
| Endo Pharmaceuticals INC. | $143.10 | 2019-2023 | Xiaflex, Aveed |
| Rochester Medical Corporation | $131.83 | 2019-2020 |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$136,647.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.